Intracavitary infusion of lobaplatin combined with Endostar in treatment of malignant pleural effusion in non-small cell lung cancer

Abstract

Objective To evaluate the efficacy and adverse reaction of intracavitary infusion of lobaplatin combined with Endostar in treatment of malignant pleural effusion in non-small cell lung cancer. Methods 60 cases of NSCLC with malignant pleural effusion were randomly devided into two groups, 30 cases per group.All patients had received systemic chemotherapy, then were treated with drainage of pleural effusion by thoracentesis and catheterization.After exhaustion of pleural effusion, the trial group was treated with lobaplatin (30 mg/m2) combined with Endostar (30 mg), and the control group was treated with cisplatin (30 mg/m2) combined with Endostar (30 mg). The efficacy and adverse reaction of the two groups were observed. Results The response rate of the trial group was higher than that of the control group (80.0% vs 66.7%, χ2=3.364, P<0.05). The proportion of patients with improved KPS in the trial group was higher than that in the control group (83.3% vs 56.7%, χ2=5.079, P<0.05). The incidence of nausea/vomiting and leucopenia in the trial group was lower than that in the control group (χ2=5.934, 3.926, all P<0.05). Conclusions Intracavitary infusion of lobaplatin combined with Endostar has significant curative effect and less adverse reaction in treatment of malignant pleural effusion in non-small cell lung cancer.The quality of life is obviously improved.It is worthy of clinical promotion. Key words: Lobaplatin; Endostar; Cisplatin; Non-small cell lung cancer; Malignant pleural effusion; Intracavitary infusion